Prévisions du marché du traitement de l’hématurie en Asie-Pacifique jusqu’en 2028 – Impact du COVID-19 et analyse régionale par traitement (médicaments, thérapies et autres), indication (infections des voies urinaires, calculs rénaux, urétrite, cancer du sang, calculs vésicaux, cancer de la prostate, cystite, traumatisme , exercice vigoureux, maladie polykystique des reins, endométriose et menstruations), type (hématurie macroscopique, hématurie microscopique, hématurie idiopathique et hématurie Jogger\'™), utilisateur final (hôpitaux, cliniques et centres chirurgicaux ambulatoires et autres)
Introduction au marché
L\'hématurie est une condition médicale dans laquelle la présence de sang est détectée dans l\'urine. . Généralement, l\'urine ne contient pas de globules rouges, ce qui peut entraîner de graves problèmes pouvant également provoquer des calculs rénaux, des infections des voies urinaires et d\'autres maladies héréditaires.
De plus, l\'hématurie est à forte prévalence. les indications associées devraient soutenir la croissance du marché au cours de la période de prévision. Cependant, des cas non diagnostiqués d\'indications associées limitent la croissance du marché du traitement de l\'hématurie en Asie-Pacifique.
L\'épidémie de COVID-19 a gravement affecté l\'industrie du tourisme et imposé des perturbations dans la chaîne d\'approvisionnement ; en outre, les pays à faible revenu sont confrontés à des défis supplémentaires en raison du manque d’infrastructures de santé. Des mesures restrictives ont été mises en place en Corée du Sud, en Malaisie, à Singapour, aux Philippines et en Inde pour prévenir la transmission de maladies. Tous ces facteurs ont eu un impact modéré sur le marché du traitement de l’hématurie pendant une courte période en raison des restrictions sur la chaîne d’approvisionnement ainsi que des capacités de fabrication limitées. L\'atteinte rénale chez les patients atteints de COVID -19 peut avoir un large éventail de manifestations, notamment l\'hématurie, la protéinurie, la pyurie et l\'insuffisance rénale aiguë (IRA). Il a été rapporté que la protéinurie et l’hématurie ont une prévalence de COVID 19 plus élevée que l’AKI. D’un autre côté, l’AKI est actuellement un signe inquiétant des patients hospitalisés atteints du COVID 19 et un facteur de risque majeur de décès. Par conséquent, le marché du traitement de l\'hématurie est positivement affecté par le COVID19.
Aperçu et dynamique du marché
Le marché du traitement de l\'hématurie en Asie-Pacifique devrait atteindre 257,6 millions de dollars US d\'ici 2028, contre 211,0 millions de dollars US en 2021 ; il devrait croître à un TCAC de 2,9 % entre 2021 et 2028. Les dépenses de santé ont considérablement augmenté en raison de la prévalence croissante des indications chroniques. Les gouvernements de diverses économies investissent considérablement dans l’amélioration des infrastructures de santé. De plus, les patients des économies développées prennent conscience des traitements possibles et de la disponibilité du remboursement pour le traitement de l\'hématurie. L\'hématurie fait partie des premières indications de maladies chroniques telles que le cancer du sang, le cancer de la vessie et le cancer du rein. Ces maladies sont couvertes par diverses polices d\'assurance maladie qui facilitent le traitement des patients et réduisent la charge financière des soins de santé. Ainsi, l’amélioration des dépenses de santé et la sensibilisation des patients au traitement stimulent le marché du traitement de l’hématurie en Asie-Pacifique.
Segments clés du marché
En termes de type, le segment de l\'hématurie macroscopique représentait la plus grande part du marché du traitement de l\'hématurie en Asie-Pacifique en 2020. En termes de traitement, le segment des médicaments représentait pour la plus grande part du marché du traitement de l’hématurie en Asie-Pacifique en 2020. En termes d’indication, le segment des infections des voies urinaires représentait la plus grande part du marché du traitement de l’hématurie en Asie-Pacifique en 2020. En termes d’utilisateur final, le segment des hôpitaux représentait la plus grande part du marché du traitement de l\'hématurie en Asie-Pacifique en 2020.
Principales sources et sociétés répertoriées
Quelques sources primaires et secondaires majeures mentionnées pour la préparation de ce rapport sur le marché du traitement de l\'hématurie en Asie-Pacifique sont les sites Web des entreprises, les rapports annuels, les rapports financiers, les documents gouvernementaux nationaux et les bases de données statistiques, entre autres. autres. Les principales sociétés répertoriées dans le rapport sont AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd et Boehringer Ingelheim International GmbH.
Rapport Raisons d\'acheter
- Comprendre le paysage du marché du traitement de l\'hématurie en Asie-Pacifique et identifier les segments de marché qui sont susceptibles de garantir un rendement élevé
- Pour comprendre le paysage du marché en constante évolution et garder une longueur d\'avance face à la concurrence
- Pour planifier efficacement les fusions, acquisitions et accords de partenariat sur le marché du traitement de l\'hématurie en Asie-Pacifique en identifiant les segments avec les ventes probables les plus prometteuses
- Pour prendre des décisions commerciales éclairées à partir d\'une analyse perspicace et complète des les performances du marché de divers segments
- Pour obtenir les prévisions de revenus du marché du traitement de l\'hématurie en Asie-Pacifique en fonction de divers segments pour la période 2021-2028
SEGMENTATION DU MARCHÉ DU TRAITEMENT DE L\'HÉMATURIE EN ASIE PACIFIQUE
Par Traitement
- Médicaments
- Thérapies
- Autres
Par indication
- Infections des voies urinaires
- Calculs rénaux
- Urétrite
- Cancer du sang
- Calculs vésicaux
- Cancer de la prostate
- Cystite
- Traumatisme
- Exercice vigoureux
- Maladie polykystique des reins
- Endométriose
- Menstruation
Par Type
- Hématurie macroscopique
- Hématurie microscopique
- Hématurie idiopathique
- Hématurie de Jogger
Par utilisateur final
- Hôpitaux
- Cliniques
- Centres chirurgicaux ambulatoires (ASC)
- Autres
Par pays
- Asie-Pacifique
- Chine
- Japon
- Inde
- Corée du Sud
- Australie
- Reste de l\'Asie-Pacifique
Entreprises mentionnées
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- < span>Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Hematuria Treatment Market – By Treatment
1.3.2 Asia Pacific Hematuria Treatment Market – By Indication
1.3.3 Asia Pacific Hematuria Treatment Market – By Type
1.3.4 Asia Pacific Hematuria Treatment Market – By End User
1.3.5 Asia Pacific Hematuria Treatment Market – By Country
2. Asia Pacific Hematuria Treatment Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Hematuria Treatment Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific – PEST Analysis
4.3 Experts Opinion
5. Hematuria Treatment Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Hematuria-Associated Indications
5.1.2 Increasing Awareness About Treatment Options and Improving Healthcare Expenditure
5.2 Market Restraints
5.2.1 Undiagnosed Cases of Associated Indications
5.3 Market Opportunities
5.3.1 Increasing Opportunities for Related Treatments
5.4 Future Trends
5.4.1 Rise in Preference for Advanced Therapies
5.5 Impact Analysis
6. Hematuria Treatment Market – Asia Pacific Analysis
6.1 Asia Pacific Hematuria Treatment Market Revenue Forecast and Analysis
7. Hematuria Treatment Market Revenue and Forecast To 2028 – By Treatment
7.1 Overview
7.2 Asia Pacific Hematuria Treatment Market Share by Treatment 2020 & 2028 (%)
7.3 Drugs
7.3.1 Overview
7.3.2 Drugs: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Therapies
7.4.1 Overview
7.4.2 Therapies: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Others
7.5.1 Overview
7.5.2 Others: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8. Hematuria Treatment Market Revenue and Forecast To 2028 – By Indication
8.1 Overview
8.2 Asia Pacific Hematuria Treatment Market Share by Indication 2020 & 2028 (%)
8.3 Kidney Stones
8.3.1 Overview
8.3.2 Kidney Stones: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Urinary Tract Infections (UTI)
8.4.1 Overview
8.4.2 Urinary Tract Infections: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Urethritis
8.5.1 Overview
8.5.2 Urethritis: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Blood Cancer
8.6.1 Overview
8.6.2 Blood Cancer: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.7 Bladder Stones
8.7.1 Overview
8.7.2 Bladder Stones: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.8 Prostate Cancer
8.8.1 Overview
8.8.2 Prostate Cancer: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.9 Cystitis
8.9.1 Overview
8.9.2 Cystitis: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.10 Trauma
8.10.1 Overview
8.10.2 Trauma: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.11 Vigorous Exercise
8.11.1 Overview
8.11.2 Vigorous Exercise: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.12 Polycystic Kidney Disease
8.12.1 Overview
8.12.2 Polycystic Kidney Disease: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.13 Endometriosis
8.13.1 Overview
8.13.2 Endometriosis: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.14 Menstruation
8.14.1 Overview
8.14.2 Menstruation: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
9. Hematuria Treatment Market Revenue and Forecast To 2028 – By Type
9.1 Overview
9.2 Asia Pacific Hematuria Treatment Market, By Type 2020 & 2028 (%)
9.3 Macroscopic Hematuria
9.3.1 Overview
9.3.2 Macroscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
9.4 Microscopic Hematuria
9.4.1 Overview
9.4.2 Microscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
9.5 Idiopathic Hematuria
9.5.1 Overview
9.5.2 Idiopathic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
9.6 Jogger’s Hematuria
9.6.1 Overview
9.6.2 Jogger’s Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
10. Hematuria Treatment Market Revenue and Forecast To 2028 – By End User
10.1 Overview
10.2 Asia Pacific Hematuria Treatment Market Share by End User 2020 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Clinics
10.4.1 Overview
10.4.2 Clinics: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
10.5 Ambulatory Surgical Centers (ASC’s)
10.5.1 Overview
10.5.2 Ambulatory Surgical Centers: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
10.6 Others
10.6.1 Overview
10.6.2 Others: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Mn)
11. Asia Pacific Hematuria Treatment Market – Geographic Analysis
11.1 Asia Pacific: Hematuria Treatment Market
11.1.1 Overview
11.1.2 Asia Pacific: Hematuria Treatment Market - Revenue and Forecast to 2028 (US$ Million)
11.1.3 Asia Pacific: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.4 Asia Pacific: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.5 Asia Pacific: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.6 Asia Pacific: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7 Asia Pacific: Hematuria Treatment Market, by Country, 2021 & 2028 (%)
11.1.7.1 China: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.1.1 China: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.1.2 China: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.1.3 China: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.1.4 China: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.1.5 China: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.2 Japan: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.2.1 Japan: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.2.2 Japan: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.2.3 Japan: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.2.4 Japan: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.2.5 Japan: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.3 India: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.3.1 India: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.3.2 India: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.3.3 India: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.3.4 India: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.3.5 India: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.4 South Korea: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.4.1 South Korea: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.4.2 South Korea: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.4.3 South Korea: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.4.4 South Korea: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.4.5 South Korea: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.5 Australia: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.5.1 Australia: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.5.2 Australia: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.5.3 Australia: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.5.4 Australia: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.5.5 Australia: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
11.1.7.6 Rest of Asia Pacific: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.6.1 Rest of Asia Pacific: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.1.7.6.2 Rest of Asia Pacific: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
11.1.7.6.3 Rest of Asia Pacific: Hematuria Treatment Market, by Indication, 2019–2028 (US$ Million)
11.1.7.6.4 Rest of Asia Pacific: Hematuria Treatment Market, by Type, 2019–2028 (US$ Million)
11.1.7.6.5 Rest of Asia Pacific: Hematuria Treatment Market, by End User, 2019–2028 (US$ Million)
12. Impact Of COVID-19 Pandemic on Hematuria Treatment Market
12.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic
13. Hematuria Treatment Market–Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 AstraZeneca
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Bristol-Myers Squibb Company
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 F. HOFFMANN-LA ROCHE LTD.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 GlaxoSmithKline Plc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Janssen Pharmaceuticals
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck & Co., Inc.
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Novartis AG
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Pfizer Inc.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Sun Pharmaceutical Industries Ltd
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Boehringer Ingelheim International GmbH
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 2. Asia Pacific: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 3. Asia Pacific: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 4. Asia Pacific: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 5. China: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 6. China: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 7. China: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. China: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 9. Japan: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 10. Japan: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 11. Japan: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. Japan: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 13. India: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 14. India: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 15. India: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 16. India: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. South Korea: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 18. South Korea: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 19. South Korea: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 20. South Korea: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 21. Australia: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 22. Australia: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 23. Australia: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 24. Australia: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 25. Rest of Asia Pacific: Hematuria Treatment Market, by Treatment – Revenue and Forecast to 2028 (US$ Million)
Table 26. Rest of Asia Pacific: Hematuria Treatment Market, by Indication– Revenue and Forecast to 2028 (US$ Million)
Table 27. Rest of Asia Pacific: Hematuria Treatment Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 28. Rest of Asia Pacific: Hematuria Treatment Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 29. Organic Developments Done by Companies
Table 30. Inorganic Developments Done by Companies
Table 31. Glossary of Terms, Hematuria Treatment Market
LIST OF FIGURES
Figure 1. Hematuria Treatment Market Segmentation
Figure 2. Asia Pacific Hematuria Treatment Market Overview
Figure 3. Macroscopic Hematuria Segment Held the Largest Share of the Type Segment in Hematuria Treatment Market
Figure 4. India to Show Significant Growth During Forecast Period
Figure 5. Asia Pacific Hematuria Treatment Market, Industry Landscape
Figure 6. Asia Pacific PEST Analysis
Figure 7. Hematuria Treatment Market Impact Analysis of Drivers and Restraints
Figure 8. Asia Pacific Hematuria Treatment Market – Revenue Forecast and Analysis – 2020- 2028
Figure 9. Asia Pacific Hematuria Treatment Market Share by Treatment 2020 & 2028 (%)
Figure 10. Drugs: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 11. Therapies: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 12. Others: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 13. Asia Pacific Hematuria Treatment Market Share by Indication 2020 & 2028 (%)
Figure 14. Kidney Stones: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 15. Urinary Tract Infections: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 16. Urethritis: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 17. Blood Cancer: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 18. Bladder Stones: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 19. Prostate Cancer: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 20. Cystitis: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 21. Trauma: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 22. Vigorous Exercise: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 23. Polycystic Kidney Disease: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 24. Endometriosis: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 25. Menstruation: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 26. Asia Pacific Hematuria Treatment Market, by Type 2020 & 2028 (%)
Figure 27. Macroscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 28. Microscopic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 29. Idiopathic Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 30. Jogger’s Hematuria: Hematuria Treatment Market Revenue and Forecast to 2028(US$ Mn)
Figure 31. Asia Pacific Hematuria Treatment Market Share by End User 2020 & 2028 (%)
Figure 32. Hospitals: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 33. Clinics: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 34. Ambulatory Surgical Centers: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 35. Others: Hematuria Treatment Market Revenue and Forecast To 2028 (US$ Mn)
Figure 36. Asia Pacific: Hematuria Treatment Market, by Key Country – Revenue (2021) (US$ Million)
Figure 37. Asia Pacific: Hematuria Treatment Market Revenue and Forecast to 2028 (US$ Million)
Figure 38. Asia Pacific: Hematuria Treatment Market, by Country, 2021 & 2028 (%)
Figure 39. China: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Japan: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. India: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. South Korea: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Australia: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. Rest of Asia Pacific: Hematuria Treatment Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Impact Of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 46. Growth Strategies Done by the Companies in the Market, (%)- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific hematuria treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific hematuria treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.